CLINICAL TRIALS

Envafolimab (KN035)

TUMOR TYPE STUDY PHASE AGENT(S) INFORMATION
Ongoing Solid Tumors Phase I Study of KN035 in Chinese Subjects With Advanced Solid Tumors Phase 1 Envafolimab (KN035) NCT03101488
Not yet recruiting Solid Tumors KN035 in Patients With Advanced Multiple Primary Tumors (CPOG035-01) Phase 2 Envafolimab (KN035) NCT04182789
Ongoing Solid Tumors 89Zr-KN035 PET Imaging in Patients With Advanced Solid Tumors Phase 1 Envafolimab (KN035) NCT03638804
Ongoing Solid Tumor A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1 Envafolimab (KN035) NCT03248843
Ongoing Biliary Tract Carcinoma Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC (KN035-BTC) Phase 3 (pivotal) Envafolimab (KN035), gemcitabine, oxaliplatin NCT03478488
Ongoing Solid Tumors Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors Phase 1 Envafolimab (KN035) NCT02827968
Ongoing MSI-H Advanced Solid Tumors KN035 for dMMR/MSI-H Advanced Solid Tumors Phase 2 (pivotal) Envafolimab (KN035) NCT03667170

TRC102

TUMOR TYPE STUDY PHASE AGENT(S) INFORMATION
Ongoing, not recruiting Recurrent Glioblastoma Phase II Study of TRC102 in Combination With Temozolomide for Recurrent Glioblastoma Phase 2 TRC102 + Temodar® (temozolomide) NCT02395692
Recruiting Non-squamous Non-small Cell Lung Cancer A Phase I Study of Methoxyamine Combined With Chemo-radiation for Locally Advanced Non-squamous Non-small Cell Lung Cancer Phase 1 TRC102 + Chemoradiation NCT02535325
Recruiting Advanced Solid Tumors or Mesothelioma Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Cisplatin and Pemetrexed Ph 1b/2 TRC102 + Alimta® (pemetrexed) + cisplatin; TRC102 + Alimta NCT02535312
Recruiting Solid tumors (oral) TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas Ph 1b TRC102 + Temodar® (temozolomide) NCT01851369

TRC253

TUMOR TYPE STUDY PHASE AGENT(S) INFORMATION
Recruiting Metastatic castration-resistant prostate cancer (mCRPC) A Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients Phase 1/2a TRC253 NCT02987829

TJ004309

TUMOR TYPE STUDY PHASE AGENT(S) INFORMATION
Ongoing Solid Tutor Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer Phase 1 TJ004309, Atezolizumab NCT03835949